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Effects of porcine circovirus type 2 and mycoplasma hyopneumoniae vaccines
on nursery pig performance
Abstract
A total of 360 weanling barrows (PIC 1050, 21 d of age and 13.0 lb) were used in a 35-d study to evaluate
the effects of porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) vaccines on
nursery pig growth performance. Two commercial PCV2 vaccines were evaluated in this study: (1) a
2-dose product, Circumvent PCV (Circumvent; Intervet/Schering-Plough Animal Health, Millsboro, DE) and
(2) a 1-dose product, Ingelvac CircoFLEX (CircoFLEX; Boehringer Ingelheim Vetmedica, Inc, St. Joseph,
MO). For the M. hyo vaccine, RespiSure (Pfizer Animal Health, New York, NY), a single 2-dose product, was
used. At weaning (d 0), pens of pigs were blocked by average pig weight and randomly allotted to 1 of 6
treatments in a 3 Ã— 2 factorial arrangement composed of a combination of PCV2 vaccine (Circumvent,
CircoFLEX, or non-PCV2-vaccinated control) and M. hyo vaccine (RespiSure or non-M. hyo-vaccinated
control). There were 5 pigs per pen and 12 pens per PCV2 Ã— M. hyo vaccine treatment. All vaccines
were administered according to label directionsâ€” CircoFLEX at weaning and Circumvent and RespiSure
at weaning and 21 d later. Common diets were fed by phase to all pigs. There were no PCV2 Ã— M. hyo
vaccine interactions for any response criteria. Overall, pigs vaccinated with Circumvent had decreased
ADG (P < 0.02) and ADFI (P â‰¤ 0.01) compared with CircoFLEX-vaccinated and control pigs,
respectively. On d 35, Circumvent- vaccinated pigs weighed less (42.9 lb, P < 0.01) than pigs vaccinated
with CircoFLEX (44.4 lb) or control pigs (44.4 lb). Pigs vaccinated with RespiSure had decreased ADG
compared with control pigs (P â‰¤ 0.05) from d 14 to 21 and d 21 to 25. On d 35, RespiSure-vaccinated
pigs tended to weigh less (43.5 lb, P = 0.06) and have lower ADFI (P = 0.06) than controls (wt = 44.3 lb).
These data indicate that PCV2 and M. hyo vaccination can independently reduce feed intake and
performance of nursery pigs and that the PCV2 vaccine effect is product dependent. Although PCV2 and
M. hyo vaccines are known to improve finishing performance, their negative impact on nursery
performance must be considered when implementing vaccine strategies.; Swine Day, Manhattan, KS,
November 19, 2009
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Effects of Porcine Circovirus Type 2 and
Mycoplasma hyopneumoniae Vaccines on Nursery
Pig Performance
M. L. Potter1, A. W. Duttlinger, J. R. Bergstrom, S. S. Dritz1,
J. M. DeRouchey, M. D. Tokach, R. D. Goodband, and J. L. Nelssen

Summary

A total of 360 weanling barrows (PIC 1050, 21 d of age and 13.0 lb) were used in a
35-d study to evaluate the effects of porcine circovirus type 2 (PCV2) and Mycoplasma
hyopneumoniae (M. hyo) vaccines on nursery pig growth performance. Two commercial
PCV2 vaccines were evaluated in this study: (1) a 2-dose product, Circumvent PCV
(Circumvent; Intervet/Schering-Plough Animal Health, Millsboro, DE) and (2) a
1-dose product, Ingelvac CircoFLEX (CircoFLEX; Boehringer Ingelheim Vetmedica,
Inc, St. Joseph, MO). For the M. hyo vaccine, RespiSure (Pfizer Animal Health, New
York, NY), a single 2-dose product, was used. At weaning (d 0), pens of pigs were
blocked by average pig weight and randomly allotted to 1 of 6 treatments in a 3 × 2
factorial arrangement composed of a combination of PCV2 vaccine (Circumvent,
CircoFLEX, or non-PCV2-vaccinated control) and M. hyo vaccine (RespiSure or
non-M. hyo-vaccinated control). There were 5 pigs per pen and 12 pens per PCV2 ×
M. hyo vaccine treatment. All vaccines were administered according to label directions—CircoFLEX at weaning and Circumvent and RespiSure at weaning and 21 d
later. Common diets were fed by phase to all pigs.
There were no PCV2 × M. hyo vaccine interactions for any response criteria. Overall,
pigs vaccinated with Circumvent had decreased ADG (P < 0.02) and ADFI (P ≤ 0.01)
compared with CircoFLEX-vaccinated and control pigs, respectively. On d 35, Circumvent-vaccinated pigs weighed less (42.9 lb, P < 0.01) than pigs vaccinated with CircoFLEX (44.4 lb) or control pigs (44.4 lb). Pigs vaccinated with RespiSure had decreased
ADG compared with control pigs (P ≤ 0.05) from d 14 to 21 and d 21 to 25. On
d 35, RespiSure-vaccinated pigs tended to weigh less (43.5 lb, P = 0.06) and have lower
ADFI (P = 0.06) than controls (wt = 44.3 lb). These data indicate that PCV2 and
M. hyo vaccination can independently reduce feed intake and performance of nursery
pigs and that the PCV2 vaccine effect is product dependent. Although PCV2 and M.
hyo vaccines are known to improve finishing performance, their negative impact on
nursery performance must be considered when implementing vaccine strategies.
Key words: growth, Mycoplasma, PCV2, vaccination

Introduction

Porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) vaccines
are routinely administered to pigs during the nursery phase to lessen the severity of
disease during the finishing period. Although vaccines for both of these pathogens
have been shown to reduce severity of disease in the finishing phase, the impact on the
1
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nursery pig has not been well characterized. In addition, as use of PCV2 vaccines has
increased, field reports have emerged indicating that producers are having increased
difficulty starting or maintaining weaned pigs on feed. Speculation that nursery pig
vaccines may contribute to this problem prompted an initial study at Kansas State
University (K-State) to investigate the role of PCV2 and M. hyo vaccines in combination on growth performance (Kane et al., 20082). Results from that study demonstrated
that feed intake and subsequent gain was decreased after initial vaccination with a
2-dose PCV2 vaccine product administered concurrently with a 1-dose M. hyo vaccine
product. However, there is limited research on the effects of different vaccine products on feed intake. Therefore, the objective of this study was to determine effects of 2
commercial PCV2 vaccines and a M. hyo vaccine on nursery pig growth performance.

Procedures

Procedures used in this study were approved by the K-State Institutional Animal Care
and Use Committee. A total of 360 weanling barrows (PIC 1050, 21 d of age and
13.0 lb) were used in a 35-d growth trial at the K-State Segregated Early Wean Facility.
Pens were equipped with a single cup waterer and a 4-hole self-feeder that provided pigs
with ad libitum access to water and feed. At weaning (d 0), pens of pigs were blocked
by average pig weight and randomly allotted to 1 of 6 treatments in a 3 × 2 factorial
arrangement of PCV2 vaccine and M. hyo vaccine. The PCV2 vaccine treatments
were: a 2-dose product, Circumvent PCV (Circumvent; Intervet/Schering-Plough
Animal Health, Millsboro, DE); a 1-dose product, Ingelvac CircoFLEX (CircoFLEX;
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO); and a non-PCV2-vaccinated
control. The M. hyo vaccine treatments were: a 2-dose product, RespiSure (Pfizer
Animal Health, New York, NY) and a non-M. hyo-vaccinated control. There were
initially 5 pigs per pen and 12 pens per PCV2 vaccine × M. hyo vaccine treatment. All
3 commercially available vaccines were administered according to label directions. Pigs
in the CircoFLEX group were administered 1 mL as an intramuscular injection on d
0. Pigs in the Circumvent treatment group received intramuscular injections of 2 mL
on d 0 and 21. A single M. hyo vaccine product was tested; therefore, pigs in the RespiSure treatment group received intramuscular injections of 2 mL on d 0 and 21. All pigs
were fed common diets throughout the trial. Initially, 1 lb/pig SEW diet was budgeted,
followed by ad libitum access to a transition diet until d 8. Phase 2 diets were fed from
d 8 to d 21, and Phase 3 diets were fed from d 21 to the end of the trial. Feeders were
emptied on d 8 and 21 prior to feeding the Phase 2 and 3 diets, respectively. Pigs were
weighed and feed disappearance was determined on d 0, 4, 8, 14, 21, 25, 29, and 35 to
calculate ADG, ADFI, and F/G.
Data were analyzed as a randomized complete block design using the GLIMMIX procedure of SAS (SAS Institute Inc., Cary, NC). Fixed effects included PCV2 vaccine,
M. hyo vaccine, and their interaction. Weaning weight, the blocking factor, was a
random effect. Pen was considered the experimental unit for this analysis. Differences
between treatments were determined by using least squares means (P < 0.05).

Results and Discussion

There were no PCV2 × M. hyo vaccine interactions for the response criteria evaluated in this study. Evaluation of the main effects of PCV2 vaccine (Table 1) revealed
2

Kane et al., Swine Day 2008, Report of Progress 1001, pp. 14-20.

22

Herd Health Management

that growth rate was unaffected (P ≥ 0.01) by PCV2 treatment during the first 21 d of
the trial. Following the initial vaccination (d 0 to 8), Circumvent-vaccinated pigs had
decreased (P = 0.01) ADFI compared with CircoFLEX-vaccinated pigs, and ADFI for
control pigs was intermediate. During the d 8 to 14 period, ADFI was decreased
(P < 0.03) for Circumvent-vaccinated pigs compared with control and CircoFLEXvaccinated pigs. Gain was similar (P = 0.81) among PCV2 vaccine treatment groups for
the d 14 to 21 period. However, F/G was improved (P = 0.02) for Circumvent-vaccinated pigs from d 14 to 21 compared with CircoFLEX-vaccinated pigs, and the control
group had intermediate F/G.
From d 21 to 29, pigs vaccinated with Circumvent had decreased (P < 0.01) ADG and
ADFI compared with both the control and CircoFLEX-vaccinated pigs. There was no
difference (P ≥ 0.34) in ADG or ADFI between the control pigs and pigs vaccinated
with CircoFLEX. From d 29 to 35, PCV2 treatment did not affect (P ≥ 0.17) ADG
or F/G, although Circumvent-vaccinated pigs had numerically lower ADFI relative to
control or CircoFLEX-vaccinated pigs.
Overall (d 0 to 35), growth was decreased (P = 0.02) in pigs vaccinated with Circumvent compared with non-PCV2-vaccinated control pigs, with the majority of the
effect occurring following the second vaccination. Pigs vaccinated with CircoFLEX
had a similar (P = 0.85) overall rate of gain compared with the control group and grew
faster (P < 0.01) than pigs vaccinated with Circumvent. The decreased growth rate for
Circumvent-vaccinated pigs is attributable to their reduced (P ≤ 0.01) feed consumption compared with the control and CircoFLEX-vaccinated pigs. There was no difference (P = 0.34) in ADFI observed among the CircoFLEX-vaccinated pigs compared
with control pigs. This performance disparity resulted in Circumvent-vaccinated pigs
weighing less (42.9 lb, P < 0.01) on d 35 than CircoFLEX-vaccinated pigs (44.4 lb) or
control pigs (44.4 lb).
In the 21 d following the first vaccination, performance of pigs vaccinated with RespiSure did not differ from that of control pigs (Table 2). After the second RespiSure
vaccination, ADG and ADFI were lower (P ≤ 0.02) for vaccinated pigs compared with
controls, and F/G was unaffected (P = 0.80) by M. hyo treatment. The negative effects
of RespiSure vaccination on intake and ADG following the second administration
resulted in RespiSure-vaccinated pigs having a tendency (P = 0.10) to gain less and have
decreased (P = 0.06) ADFI from d 0 to 35 compared with control pigs. The poorer
growth performance of the RespiSure-vaccinated pigs resulted in a trend (P = 0.06) for
these pigs to have lighter d-35 weights than control pigs.
Compared with performance of control pigs in the respective treatment groups, the
pattern of negative effects was similar for both Circumvent and RespiSure vaccines,
whereas CircoFLEX-vaccinated pigs did not appear to experience negative impacts
from vaccination. For the Circumvent-vaccinated and RespiSure-vaccinated pigs, the
biggest reduction in performance was observed after the second vaccination.
Although there was no PCV2 × M. hyo vaccine interaction, d-35 weights for the 6
different PCV2 × M. hyo treatments measured against non-vaccinated control pigs
showed that approximately a 1.5-lb reduction in weight may be due to Circumvent
23
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vaccine and an additional 0.8 lb reduction in weight may be due to RespiSure vaccination. Therefore, when Circumvent and RespiSure products were used in conjunction,
these negative effects were additive and resulted in a 2.5 lb lighter d-35 weight (Figure 1).
These findings support previous research conducted at K-State (Kane et al., 2008) in
which following an initial vaccination with both Circumvent PCV and RespiSure-One
(Pfizer Animal Health, New York, NY), vaccinated pigs had lower (P < 0.01) ADG
and ADFI (d 4 to 8 and d 0 to 8) and weighed less (P < 0.01) on d 8 than pigs not
vaccinated until d 8. In the current study, this difference in feed intake for Circumventvaccinated pigs was noted within the first 21 d after initial vaccination, and the lower
feed consumption continued and negatively affected growth rate following the second
vaccination. The second Circumvent vaccination appears to be an additional stressor
and has substantial negative effects on nursery performance that are not recovered
from within 14 d after the second vaccination. It is likely that vaccines factor into how
pigs start or are maintained on feed, although the severity of the response as well as its
timing may be vaccine dependent. We believe the effects on feed intake noted in this
study may be a factor in field reports that have indicated that producers are having
increased difficulty starting or maintaining pigs on feed postweaning.
These data demonstrate that nursery pig performance differs because of the PCV2
vaccine product selected and M. hyo vaccination. However, this study was not designed
to evaluate efficacy of these products. Therefore, no conclusions as to vaccine selection
for best control of clinical disease from these infections should be drawn. However,
these data indicate that PCV2 and M. hyo vaccination can independently reduce feed
intake and performance of nursery pigs and that the PCV2 vaccine effect is product
dependent. Although PCV2 and M. hyo vaccines are known to improve finishing
performance, their negative effect on nursery performance must be considered when
implementing vaccine strategies.
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Table 1. Effect of PCV2 vaccines on nursery pig growth performance, feed intake, and
feed efficiency1
PCV2 treatment2
Item
Control
Circumvent
CircoFLEX
SEM
d 0 to 8
     ADG, lb
0.28
0.26
0.29
0.02
ab
a
b
     ADFI, lb
0.28
0.26
0.29
0.01
     F/G
1.02
1.03
1.04
0.03
d 8 to 14
     ADG, lb
0.73
0.68
0.70
0.03
a
b
a
     ADFI, lb
0.96
0.87
0.95
0.04
     F/G
1.31
1.29
1.37
0.03
d 14 to 21
     ADG, lb
1.04
1.03
1.02
0.03
     ADFI, lb
1.55
1.48
1.54
0.04
ab
a
b
     F/G
1.50
1.45
1.52
0.03
d 21 to 29
     ADG, lb
1.07a
0.96b
1.10a
0.03
a
b
a
     ADFI, lb
1.70
1.57
1.72
0.04
     F/G
1.60
1.65
1.58
0.03
d 29 to 35
     ADG, lb
1.50
1.48
1.50
0.04
     ADFI, lb
2.20
2.16
2.25
0.06
     F/G
1.47
1.46
1.51
0.02
d 0 to 35
     ADG, lb
0.89a
0.85b
0.90a
0.02
a
b
a
     ADFI, lb
1.29
1.23
1.32
0.03
     F/G
1.45
1.45
1.47
0.01
Weight, lb
     d 0
12.9
13.0
13.0
0.6
     d 21
26.9
26.3
26.6
0.9
a
b
a
     d 35
44.4
42.9
44.4
1.2
Results are reported as least squares means. A total of 360 barrows (PIC 1050) were used in a 35-d study. There
were 5 pigs per pen and 24 pens per PCV2 treatment.
2
PCV2 vaccine treatments were: 2 groups of vaccinates receiving either 2 mL Circumvent PCV administered
intramuscularly on d 0 and 21 or 1 mL Ingelvac CircoFLEX administered intramuscularly on d 0 and a nonPCV2-vaccinated control group.
ab
Within a row, means without a common superscript differ (P < 0.05).
1
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Table 2. Effect of M. hyo vaccines on nursery pig growth performance, feed intake, and
feed efficiency1
M. hyo treatment2
Item
Control
RespiSure
SEM
Probability, P <
d 0 to 8
     ADG, lb
0.28
0.27
0.01
0.44
     ADFI, lb
0.28
0.27
0.01
0.40
     F/G
1.03
1.03
0.03
0.88
d 8 to 14
     ADG, lb
0.69
0.72
0.03
0.10
     ADFI, lb
0.93
0.93
0.04
0.82
     F/G
1.35
1.29
0.02
0.06
d 14 to 21
     ADG, lb
1.05
1.01
0.03
0.05
     ADFI, lb
1.54
1.51
0.04
0.25
     F/G
1.47
1.50
0.02
0.23
d 21 to 29
     ADG, lb
1.07
1.01
0.03
0.02
     ADFI, lb
1.71
1.62
0.04
<0.01
     F/G
1.61
1.60
0.02
0.80
d 29 to 35
     ADG, lb
1.51
1.48
0.04
0.31
     ADFI, lb
2.24
2.16
0.06
0.03
     F/G
1.49
1.47
0.02
0.26
d 0 to 35
     ADG, lb
0.89
0.87
0.02
0.10
     ADFI, lb
1.30
1.26
0.03
0.06
     F/G
1.46
1.45
0.01
0.57
Weight, lb
     d 0
12.9
13.0
0.6
0.22
     d 21
26.7
26.5
0.9
0.50
     d 35
44.3
43.5
1.2
0.06
Results are reported as least squares means. A total of 360 barrows (PIC 1050) were used in a 35-d study. There
were 5 pigs per pen and 36 pens per M. hyo treatment.
2
M. hyo vaccine treatments were: Vaccinates receiving 2 mL RespiSure administered intramuscularly on d 0 and
21 and a non-M. hyo-vaccinated control group.
1
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50.0

Weight, lb

PCV2 × M. hyo: P = 0.68
SEM = 1.3

45.0

44.7

M. hyo control
RespiSure

44.6

44.1

44.1

43.6
42.2

40.0

PCV2 control

Circumvent

CircoFLEX

PCV2 Treatment

Figure 1. Effect of PCV2 and M. hyo vaccination on d-35 pig weight.
PCV2 vaccine treatments were: PCV2 controls (No PCV2 vaccine), Circumvent (pigs vaccinated with 2 mL Circumvent PCV administered intramuscularly on d 0 and 21), and CircoFLEX (pigs vaccinated with 1 mL Ingelvac CircoFLEX administered intramuscularly on d
0). M. hyo vaccine treatments were: M. hyo controls (No M. hyo vaccine) and RespiSure (pigs
vaccinated with 2 mL RespiSure administered intramuscularly on d 0 and 21.)
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